Brand and Other Names:Aciphex, Aciphex Sprinkle
- Classes: Proton Pump Inhibitors
Dosing & Uses
Dosage Forms & Strengths
Indicated for short-term (up to 4 weeks) treatment in healing and symptomatic relief of duodenal ulcers
20 mg PO qDay after morning meal for up to 4 weeks; to achieve healing, some patients may require additional therapy
Helicobacter Pylori Eradication
In combination with amoxicillin and clarithromycin for treatment of H pylori infection and duodenal ulcer disease (active or history within past 5 yr)
20 mg PO BID for 7 days with morning and evening meals; take with amoxicillin 1000 mg PO BID and clarithromycin 500 mg BID
Gastroesophageal Reflux Disease
Healing or erosive or ulcerative GERD
- 20 mg PO qDay for 4-8 weeks; if not healed after 8 weeks, an additional 8-week course may be considered
- Maintenance dosing (20 mg/day for up to 12 months) shown to reduce relapse rates
- Treatment of daytime and nighttime heartburn and other symptoms associated with GERD
- 20 mg PO qDay for 4 weeks; if symptoms not completely resolved after 4 weeks, an additional course may be considered
Long-term treatment of pathologic hypersecretory conditions, including Zollinger-Ellison syndrome
60 mg PO qDay initially; may increase to 100 mg PO qDay or 60 mg PO q12hr
- Continue use as long as clinically needed; some patients with SE have been treated continuously for up to 1 yr
Administer with or without meals
Swallow tablet whole; do not chew or crush
Renal impairment: Dose adjustment not necessary
- Mild to moderate: Dose adjustment not necessary
- Severe: Not studied
Dosage Forms & Strengths
Gastroesophageal Reflux Disease
- Indicated for short-term treatment of symptomatic GERD in adolescents
- <12 years: Safety and efficacy not established
- ≥12 years: 20 mg PO qDay for up to 8 weeks
Delayed-release capsule (sprinkles)
- <1 year: Safety and efficacy not established
- 1-12 years (<15 kg): 5 mg PO qDay 30 minutes before a meal, for up to 12 weeks; may increase to 10 mg/day if inadequate response
- 1-12 years (≥15 kg): 10 mg PO qDay 30 minutes before a meal, for up to 12 weeks
- Administer with or without meals
- Swallow tablet whole; do not chew or crush
- Take 30 minutes before a meal
- Granules should not be chewed or crushed; open capsule and sprinkle entire contents on small amount of soft food (eg, applesauce, fruit- or vegetable-based baby food, or yogurt) or empty contents into a small amount of liquid (eg, infant formula, apple juice, or pediatric electrolyte solution)
- The whole dose should be taken within 15 minutes of preparation
- Food or liquid should be at or below room temperature; do not store mixture for future use
Serious - Use Alternative
Significant - Monitor Closely
Abdominal pain (4%)
Osteoporosis related fracture
Toxic epidermal necrolysis
Hypersensitivity to rabeprazole or other proton pump inhibitors (PPIs)
PPIs are possibly associated with increased incidence of Clostridium difficile-associated diarrhea (CDAD); consider diagnosis of CDAD for patients taking PPIs with diarrhea that does not improve
Liver disease: May require dosage reduction
Atrophic gastritis may occur as has occurred with omeprazole
Contains enteric coated granules (acid labile); do not chew or crush
Use of proton pump inhibitors may increase risk of salmonella and campylobacter infection
Reduce of symptoms does not eliminate presence of gastric malignancy
Published observational studies suggest that PPI therapy may be associated with an increased risk of osteoporosis-related fractures of the hip, wrist, or spine; particularly with prolonged (>1 yr), high-dose therapy
Decreased gastric acidity increases serum chromogranin A (CgA) levels and may cause false positive diagnostic results for neuroendocrine tumors; temporarily discontinue PPIs before assessing CgA levels
Hypomagnesemia may occur with prolonged use (ie, >1 yr); adverse effects, such as tetany, arrhythmias, or seizures, may result; in 25% of cases reviewed, magnesium supplementation alone did not improve low serum magnesium levels, and the PPI had to be discontinued
Monitor for increases in INR and prothombin time when coadministered with warfarin
Daily long-term use (e.g., longer than 3 years) may lead to malabsorption or a deficiency of cyanocobalamin
Acute interstitial nephritis reported in patients taking proton pump inhibitors
Concomitant use of proton pump inhibitors with methotrexate, primarily at high dose, may elevate and prolong serum concentrations of methotrexate and/or its metabolite, possibly leading to methotrexate toxicities; in high-dose methotrexate administration, a temporary withdrawal of the PPI may be considered in some patients
Pregnancy & Lactation
Pregnancy category: C
Lactation: Unknown whether rabeprazole is distributed into breast milk; use caution
A:Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B:May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.
C:Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.
D:Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.
X:Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.
NA:Information not available.
Mechanism of Action
Proton pump inhibitor (PPI); binds to H+/K+-exchanging ATPase (proton pump) in gastric parietal cells, blocking acid secretion
Onset: Within 1 hr
Duration: 24 hr
Peak plasma time: 2-5 hr (tablet); 1-6.5 hr (capsule)
Protein bound: 95-98%
Metabolism: Liver; extensively by hepatic P450 enzyme CYP2C19; second pathway through CYP3A4; also by non-enzymatic reduction
Metabolites (presumed inactive): Rabeprazole thioether, sulfone metabolite, desmethyl metabolite, desmethyl thioether, thioether carboxylic acid
CYP2C19 substrate (minor)
Half-life elimination: 1-2 hr, depending on dose
Total body clearance: 4-8 mL/min/kg
Excretion: Urine (90%); feces (10%)
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
The above information is provided for general informational and educational purposes only. Individual plans may vary and formulary information changes. Contact the applicable plan provider for the most current information.
|1||This drug is available at the lowest co-pay. Most commonly, these are generic drugs.|
|2||This drug is available at a middle level co-pay. Most commonly, these are "preferred" (on formulary) brand drugs.|
|3||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs.|
|4||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|5||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|6||This drug is available at a higher level co-pay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.|
|NC||NOT COVERED – Drugs that are not covered by the plan.|
Drugs that require prior authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of the drug that will be covered.
Drugs that have step therapy associated with each prescription. This restriction typically requires that certain criteria be met prior to approval for the prescription.
Drugs that have restrictions other than prior authorization, quantity limits, and step therapy associated with each prescription.
Select a box to add or remove a plan.
Select a class to view formulary status for similar drugs